---
title: "Hengrui Wins NMPA Nod to Move Cervical Cancer Combo to First-Line Use"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293620453.md"
description: "Jiangsu Hengrui Pharmaceuticals received NMPA approval to upgrade its camrelizumab and famitinib combo to first-line treatment for recurrent or metastatic cervical cancer. This regulatory milestone expands the eligible patient pool, enhances commercial potential, and strengthens Hengrui's position in China's oncology market. The company remains a leader in innovative therapies, with analysts maintaining a Buy rating on its stock."
datetime: "2026-07-23T12:37:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293620453.md)
  - [en](https://longbridge.com/en/news/293620453.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293620453.md)
---

# Hengrui Wins NMPA Nod to Move Cervical Cancer Combo to First-Line Use

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has shared an update.

Jiangsu Hengrui Pharmaceuticals and its subsidiary Suzhou Suncadia Biopharmaceuticals have received approval from China’s National Medical Products Administration to market their innovative drug combo, camrelizumab for injection with famitinib malate capsules. The regimen is now cleared as a first-line treatment for patients with recurrent or metastatic cervical cancer, upgrading its prior positioning from second-line to first-line therapy in advanced disease.

The approval strengthens Hengrui’s presence in oncology, particularly in targeted immunotherapy for gynecologic cancers, and underscores the company’s ability to move pipeline assets into earlier lines of care. This shift to first-line use could expand the eligible patient pool, enhance the commercial potential of camrelizumab and famitinib, and reinforce the firm’s competitive standing in China’s fast-growing market for innovative cancer treatments.

The most recent analyst rating on (HK:1276) stock is a Buy  
with a HK$92.00 price target.  
To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock,  
see the HK:1276 Stock Forecast page.

**More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H**

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading Chinese pharmaceutical company focused on innovative therapies, including biologic and chemical drugs, for oncology and other serious diseases. Through its subsidiaries such as Suzhou Suncadia Biopharmaceuticals, the group targets both domestic and international markets with advanced treatments aimed at unmet clinical needs.

**Average Trading Volume:** 4,240,529

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$418.2B

For a thorough assessment of 1276 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)

## Related News & Research

- [Hengrui Pharma wins China approval for camrelizumab-famitinib combo as 1L cervical cancer treatment](https://longbridge.com/en/news/293617770.md)
- [Hengrui Pharma Wins First China Approval for Home-Grown Long-Acting Insulin Analog](https://longbridge.com/en/news/294227320.md)
- [FDA Panel Backs Wider Access To Six Peptide Therapies, Citing Grey Market Concerns](https://longbridge.com/en/news/294233160.md)
- [12:02 ETBeverly Hills Concierge Physician Dr. David Nazarian Discusses the Growing Demand for Physician-Supervised Peptide Therapy](https://longbridge.com/en/news/294535853.md)
- [07:57 ETEVERSANA Selected by Innovacell as Commercialization Partner to Advance Novel Cell Therapy ICEF15 in the United States](https://longbridge.com/en/news/294360419.md)